Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1614 1621 1624 1627 1629 1693
This examiner grants 42% of resolved cases
Bong-Sook Baek serves in Art Unit 1611 of Tech Center 1600. The examiner has 923 resolved cases and an allowance rate of 41.7 percent. The median days to allowance is 1140, reflecting a challenging path to grant. These 923 resolved cases provide a robust data set for evaluating the examiner's performance in Art Unit 1611.
The interview lift is 69.9 percent, which is an exceptionally high increase over the 41.7 percent baseline allowance rate. This suggests that interviews are almost essential for success, as they provide a massive boost to the probability of grant. Practitioners should prioritize interviews to navigate the 1140-day median pendency and improve their chances of success. The 69.9 percent lift is the most significant metric in this profile, indicating that verbal advocacy is highly productive. Applicants can use the 1140-day median to set expectations for their timeline in Tech Center 1600 while relying on the 69.9 percent lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | Non-Final OA | Beam Therapeutics Inc. |
| 18668774 | METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077 | Non-Final OA | Genentech, Inc. |
| 18696604 | HAIR CARE COMPOSITIONS, METHOD FOR PROVIDING IMPROVED CURLS DEFINITION TO THE HAIR AND METHOD OF TREATING HAIR | Final Rejection | L'OREAL |
| 18907757 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18830475 | TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | Non-Final OA | Global Blood Therapeutics, Inc. |
| 18801886 | Cardiosafe Antidiabetic Therapy | Final Rejection | Boehringer Ingelheim International GmbH |
| 18024679 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BRAIN DAMAGE AND MILD COGNITIVE IMPAIRMENT COMPRISING GLUTAMINE AS EFFECTIVE COMPONENT | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY |
| 18321965 | COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER COMPRISING COMPOUND DERIVED FROM DENDROPANAX MORBIFERUS | Non-Final OA | JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy